Altimmune (ALT) Stock Forecast & Price Target

Altimmune Inc. demonstrates a positive outlook driven by its key candidate, pemvidutide, which targets metabolic dysfunction-associated steatohepatitis (MASH) with a dual-action mechanism that shows promise in clinical trials and offers favorable tolerability. The company's strong financial position, supported by approximately $340 million in pro-forma cash, enhances its capacity to fund Phase 3 MASH execution and pursue additional therapeutic indications for pemvidutide. Furthermore, the strategic development pipeline, including upcoming Phase 2 trial results for alcohol use disorder and breakthrough therapy designation that facilitates expedited regulatory discussions, positions Altimmune favorably within the biopharmaceutical landscape, potentially expanding its market reach beyond MASH.

Altimmune Inc faces significant development and commercialization risks that are likely to impede its business prospects and negatively impact its stock performance. The regulatory pathway for its key candidate, pemvidutide, remains uncertain, particularly in the context of metabolic dysfunction-associated steatohepatitis (MASH), as no drugs have been approved by major regulatory bodies in this space, which could adversely affect market penetration and future revenue projections. Additionally, the need for capital to advance Phase 3 trials may lead to dilution and further complicate financial forecasts, as seen in the reported earnings per share for Q4 2025 falling below expectations.